Global Targeted Sequencing and Resequencing Market Size study & Forecast, by Technology (Sequencing, Resequencing) by Type (DNA, RNA), by Application (Clinical Application, Plant & animal sciences, Drug development, Others), by End-use (Hospitals & clinic

Global Targeted Sequencing and Resequencing Market Size study & Forecast, by Technology (Sequencing, Resequencing) by Type (DNA, RNA), by Application (Clinical Application, Plant & animal sciences, Drug development, Others), by End-use (Hospitals & clinics, Academic Research, Others) and Regional Analysis, 2022-2029

Global Targeted Sequencing and Resequencing Market is valued at approximately USD 4.1 billion in 2021 and is anticipated to grow with a healthy growth rate of more than 22.59% over the forecast period 2022-2029. Targeted Sequencing is a method of detecting unusual variants in a certain set of genes whereas, Resequencing is a method in which a subset of genes is isolated and sequenced. Targeted Sequencing and Resequencing are the methods used for the sequencing of a portion of a person's genome to look for sequence discrepancies between that person and the species' typical genome. Shotgun and high throughput are the two main types of DNA sequencing. Targeted sequencing and resequencing are used for the detection of mutations in DNA caused by various congenital diseases. In comparison to WGS and other survey methods, it provides a proper analysis of the results and prevents the erroneous interpretation of sequencing data. Cost-saving advantages of full genome sequencing, increasing R&D investments in the pharmaceutical industry, advantages of amplicon sequencing and targeted gene panels and Technological advancements in sequencing technology are the factors driving the major market growth.

According to the National Library of Medicine, full genome sequencing costs about $10 million in 2007. Since then, sequencing prices have decreased rapidly, and it is expected that the $1000 genome will soon become a reality. Additionally, in 2019, R&D expenditures in the pharmaceutical business were $83 billion. Particularly, between 2015 and 2019, investment in pharmaceutical R&D surged by about 50%. Increasing R&D investments leads to the development of innovative Sequencing and Resequencing techniques. Cost-saving advantages of full genome sequencing and increasing research and development investments in the pharmaceutical industry are the major factors driving the growth of the market. Other components driving market increase are the advantages of amplicon sequencing and targeted gene panels and Technological advancements in sequencing technology. Furthermore, emerging digital next-generation sequencing technology and advancements to perform sequencing in less time are the factors creating major market opportunities in the forecast period. However, the high cost of maintaining Targeted Sequencing and Resequencing stifles market growth throughout the forecast period of 2022-2029.

The key regions considered for the Global Targeted Sequencing And Resequencing Market study includes Asia Pacific, North America, Europe, Latin America, and Rest of the World. North America dominated the market in terms of revenue, owing to the dominance of market players, increasing advancements in technology, and the region's increasing development of sequencing capabilities. Asia Pacific is expected to grow with the highest CAGR during the forecast period, owing to factors such as increasing investments in research & development, the prevalence of advanced technology for drug development and discovery, and the geographic expansion of key players.
Major market player included in this report are:
Illumina, Inc.
F. Hoffmann-La Roche Ltd
Agilent Technologies Inc.
GATC Biotech Ag
Oxford Nanopore Technologies
Thermo Fisher Scientific, Inc.
DNASTAR Inc.
QIAGEN
BGI
Perkin Elmer, Inc.
Recent Developments in the Market:
In January 2021, Illumina announced several collaborations between Merck, Myriad Genetics, Kura Oncology, and Bristol Myers Squibb that support the company's goal of creating standardized, widely available tools for precision oncology.
In Aug 2022, The Medical Device Innovation Consortium (MDIC) introduced Somatic Reference Samples (SRS), an initiative to improve NGS-based cancer diagnosis by validating and developing public genomic datasets and therapeutically relevant samples.
Global Targeted Sequencing And Resequencing Market Report Scope:
Historical Data 2019-2020-2021
Base Year for Estimation 2021
Forecast period 2022-2029
Report Coverage Revenue forecast, Company Ranking, Competitive Landscape, Growth factors, and Trends
Segments Covered Technology, Type, Application, End-use, Region
Regional Scope North America; Europe; Asia Pacific; Latin America; Rest of the World

The objective of the study is to define market sizes of different segments & countries in recent years and to forecast the values to the coming years. The report is designed to incorporate both qualitative and quantitative aspects of the industry within countries involved in the study.

The report also caters detailed information about the crucial aspects such as driving factors & challenges which will define the future growth of the market. Additionally, it also incorporates potential opportunities in micro markets for stakeholders to invest along with the detailed analysis of competitive landscape and Technology offerings of key players. The detailed segments and sub-segment of the market are explained below:
By Technology:
Sequencing
Re-sequencing

By Type:
DNA
RNA

By Application:
Clinical Application
Plant & animal sciences
Drug development
Others

By End-use:
Hospitals & clinics
Academic Research
Others

By Region:
North America
U.S.
Canada
Europe
UK
Germany
France
Spain
Italy
ROE
Asia Pacific
China
India
Japan
Australia
South Korea
RoAPAC
Latin America
Brazil
Mexico
Rest of the WorldCompanies Mentioned
Illumina, Inc.
F. Hoffmann-La Roche Ltd
Agilent Technologies Inc.
GATC Biotech Ag
Oxford Nanopore Technologies
Thermo Fisher Scientific, Inc.
DNASTAR Inc.
QIAGEN
BGI
Perkin Elmer, Inc.

Please note:The single user license is non-downloadable and non-printable. Global Site license allows these actions.